4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001437749-26-006421
CMO & Head of Development sold 3,611 shares at $15.02 ($54,220)
- CMO & Head of Development acquired 3,611 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Watkins Tim · CMO & Head of Development
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-02 | Exercise or conversion : show line 1 in the form 10b5-1 | +3,611 | $4.50 | $16,250 | 3,611 | D |
| 2026-03-02 | Sale : show line 2 in the form 10b5-1 | −3,611 | $15.02 | $54,220 | 0 | D |
| Open-market sales · 3,611 sh · avg $15.02 · $54,220 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-02 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −3,611 | 249,167 | D |
Loading xslF345X05/rdgdoc.xml…